Payment overview · 2025
General Payments
$770.98
40 reported records · 13 companies
Healthcare provider profile · identity verified
Amanda Lynn Kincaid
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BLOWING ROCK, NC · NPI 1225672959
Verified facts
What the public records show
CMS Open Payments records show Amanda Lynn Kincaid received $770.98 in general payments during 2025 across 40 reported records.
Lundbeck LLC accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $167.22 | 21.7% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $156.87 | 20.4% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.62 | 13.4% | 6 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $56.48 | 7.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $53.84 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.52 | 6.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.36 | 6.7% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $40.38 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.46 | 2.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.93 | 2.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.82 | 2.3% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $16.65 | 2.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.83 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $770.98 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $167.22 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $83.61 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.06 | 3 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $56.48 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $53.84 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.36 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.56 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $41.28 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 70 |
| Alprazolam | Alprazolam | 255 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 242 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 188 | 24 |
| Lisinopril | Lisinopril | 186 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 48 |
| Gabapentin | Gabapentin | 141 | 51 |
| Lorazepam | Lorazepam | 128 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 29 |
| Losartan Potassium | Losartan Potassium | 106 | 29 |
| Potassium Chloride | Potassium Chloride | 97 | 24 |
| Trazodone Hcl | Trazodone Hcl | 96 | 27 |
| Clonazepam | Clonazepam | 94 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 38 |
| Omeprazole | Omeprazole | 93 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 29 |
| Mounjaro | Tirzepatide | 83 | 16 |
| Meloxicam | Meloxicam | 82 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 21 |
| Furosemide | Furosemide | 73 | 23 |
| Eliquis | Apixaban | 71 | 15 |
| Montelukast Sodium | Montelukast Sodium | 70 | 22 |
| Metformin Hcl Er | Metformin Hcl | 67 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 18 |
| Ozempic | Semaglutide | 62 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 11 |
| Ezetimibe | Ezetimibe | 59 | 16 |
| Simvastatin | Simvastatin | 59 | 17 |
| Metformin Hcl | Metformin Hcl | 58 | 17 |
| Pregabalin | Pregabalin | 52 | 12 |
| Azelastine Hcl | Azelastine Hcl | 51 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 13 |
| Baclofen | Baclofen | 43 | 13 |
| Ondansetron Odt | Ondansetron | 43 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 11 |
| Famotidine | Famotidine | 40 | 14 |
| Azithromycin | Azithromycin | 38 | 24 |
| Allopurinol | Allopurinol | 37 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 22 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Atenolol | Atenolol | 27 | suppressed |
| Prednisone | Prednisone | 27 | 20 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 12 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $770.98 · 40 records | Lundbeck LLC | AIRSUPRA, Azstarys, BREZTRI, CAPLYTA, Dyanavel XR, FARXIGA, INSPIRE, JARDIANCE, Kerendia, Ohtuvayre, Ozempic, QULIPTA, UBRELVY, VRAYLAR, VYEPTI, Veozah, Wegovy, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error